MarketPulse

liver disease

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Zealand Pharma

Boehringer's Obesity Drug Survodutide Posts Strong Phase 3 Results, Boosting Zealand Pharma

Boehringer's survodutide shows 16.6% weight loss in Phase 3 trial, benefiting Zealand Pharma with EUR 315M in potential milestone payments and ongoing royalties.
ZLDPYPhase 3 trialweight loss
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Altimmune Raises $225M in Oversubscribed Offering to Fund MASH Trial

Altimmune raises $225M in oversubscribed offering to fund Phase 3 MASH trial, pricing 64.25M shares at $3.00 each.
ALTwarrantspublic offering
BenzingaBenzinga··Prnewswire

Galmed Files 2025 Annual Report as Aramchol Advances Through Clinical Pipeline

Galmed files 2025 annual report detailing Aramchol development for NASH and cardiometabolic diseases, including clinical trial progress and regulatory disclosures.
GLMDFDA approvalclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Prime Medicine, Inc.

Prime Medicine to Present at Three Major Biotech Conferences in March

Prime Medicine will present at three major biotech conferences in March 2026, including TD Cowen and Citizens Life Sciences, with webcasts available afterward.
PRMEclinical developmentinvestor conference